The stock of Channel Therapeutics Corporation (CHRO) has gone down by -30.08% for the week, with a 137.77% rise in the past month and a 177.29% rise in the past quarter. The volatility ratio for the week is 21.79%, and the volatility levels for the past 30 days are 35.29% for CHRO. The simple moving average for the past 20 days is -2.79% for CHRO’s stock, with a 56.79% simple moving average for the past 200 days.
Is It Worth Investing in Channel Therapeutics Corporation (AMEX: CHRO) Right Now?
Additionally, the 36-month beta value for CHRO is 3.95. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CHRO is 1.23M and currently, short sellers hold a 0.35% ratio of that float. The average trading volume of CHRO on February 05, 2025 was 897.90K shares.
CHRO) stock’s latest price update
The stock of Channel Therapeutics Corporation (AMEX: CHRO) has decreased by -19.25 when compared to last closing price of 2.13.Despite this, the company has seen a loss of -30.08% in its stock price over the last five trading days. globenewswire.com reported 2024-12-20 that FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical’s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.
CHRO Trading at 56.69% from the 50-Day Moving Average
After a stumble in the market that brought CHRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.33% of loss for the given period.
Volatility was left at 35.29%, however, over the last 30 days, the volatility rate increased by 21.79%, as shares surge +115.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +217.93% upper at present.
During the last 5 trading sessions, CHRO fell by -30.08%, which changed the moving average for the period of 200-days by -13.57% in comparison to the 20-day moving average, which settled at $1.77. In addition, Channel Therapeutics Corporation saw 168.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CHRO starting from Malamut Richard, who purchase 10,400 shares at the price of $0.94 back on Sep 12 ’24. After this action, Malamut Richard now owns 91,565 shares of Channel Therapeutics Corporation, valued at $9,825 using the latest closing price.
Francis Knuettel II, the CEO, Pres., CFO, Treas & Secty of Channel Therapeutics Corporation, purchase 3,500 shares at $0.97 during a trade that took place back on Sep 13 ’24, which means that Francis Knuettel II is holding 547,710 shares at $3,395 based on the most recent closing price.
Stock Fundamentals for CHRO
The total capital return value is set at 6.74.
Based on Channel Therapeutics Corporation (CHRO), the company’s capital structure generated 2.66 points at debt to capital in total, while cash flow to debt ratio is standing at -2.4. The debt to equity ratio resting at -1.6. The interest coverage ratio of the stock is -11.48.
Currently, EBITDA for the company is -6.86 million with net debt to EBITDA at -0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In conclusion, Channel Therapeutics Corporation (CHRO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
